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Background
Macaque studies of antiretroviral-containing microbicide
gels administered rectally or vaginally followed by SIV
challenge have documented priming of SIV-specific T
cell responses in the blood of protected animals. This
concept has been termed “chemo-vaccination”, where
aborted viral replication is thought to leave an immune
footprint of exposure, which may augment protection
provided by microbicides/PrEP. We investigated whether
T cell responses were detectable in women participating
in CAPRISA004 1% tenofovir microbicide trial, which
showed 39% efficacy in reducing HIV acquisition.
Methods
Thirty-eight HIV-uninfected participants were selected
based on consistently high gel use and a high number of
recorded sex acts over the duration of the trial. Cryopre-
served PBMC were stimulated with HIV-1 peptide pools
based on the HIV-1 clade C proteome, and IFN-gamma
production was measured by the ELISPOT assay. Positive
response were defined as >55 SFU/106 PBMC. Samples
were tested at the visit at which preceding monthly coital
activity was the participant’s highest, and at study exit.
Assays were conducted blinded to placebo or tenofovir
arm.
Results
T cell responses were detected in 1/18 tenofovir and 2/13
placebo participants at the high gel use visit. Responses
were of low magnitude (between 60 and 100 SFU/106
PBMC), and directed at peptide pools from HIV Gag, Pol,
Nef and Env. T cell responses were not detected at the
exit visit. These data suggest that HIV-specific responses
are infrequently detected in blood in uninfected partici-
pants from a clinical trial of a vaginal microbicide, and
where present, are of low magnitude and transient.
Conclusion
Magnitude and timing of viral exposure may account for
differences in detecting systemic T cell responses between
preclinical studies in non-human primates and a human
clinical trial of a vaginal microbicide.
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